AUR-107 is under clinical development by Aurigene Oncology and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AUR-107’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AUR-107 overview
AUR-107 is under development for the treatment of non-small cell lung cancer, lymphoma, leukemia, bladder cancer, gastric cancer, urothelial cancer, kidney cancer, colon cancer, and esophageal cancer, breast cancer and prostate cancer. It is administered through oral route. The therapeutic candidate targets CBP/P300 proteins.
Aurigene Oncology overview
Aurigene Oncology, a subsidiary of Dr. Reddy’s Laboratories Ltd, is a biotechnology company that develops small molecule and peptide therapeutics. The company develops small molecule and peptide drug candidates for oncology and inflammatory diseases. It owns integrated drug discovery infrastructure from hit generation to pre-clinical development. Aurigene’s pipeline portfolio consists of AUR-101, CA-170, AUR-109, AUR-108, AUR-103, AUR-105P, AUR-106 and AUR-107 among others. The company’s therapeutic areas include psoriasis, psoriatic arthritis, ankylosing spondylitis, non-small cell lung cancer, lung fibrosis, leukaemia and lymphoma, multiple solid tumors, medulloblastoma, and cancers of bladder, kidney, lung, breast, ovary and liver, among others. It works in collaboration with mid-pharma companies. Aurigene is headquartered in Bangalore, Karnataka, India.
For a complete picture of AUR-107’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
